Is SS-31 safe?

Emerging Research

Side effects, risks, and safety considerations based on available research.

Research status

SS-31 has some clinical data but research is still developing. Safety data exists but may come from small studies, short-term trials, or specific populations that may not reflect your situation.

Known concerns & side effects

  • not FDA-approved — failed to meet primary endpoint in pivotal Barth syndrome trial despite showing biological activity
  • injection site reactions reported in clinical trials
  • long-term safety data in healthy individuals is very limited
  • most aging-related evidence comes from animal models, not humans
  • sourcing from research chemical suppliers carries purity and contamination risks

Use caution with

not enough safety data to identify specific drug interactionscaution with other mitochondrial-targeted compounds — combined effects are unstudiedconsult a physician before use

Relevant safety research

Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction

2020Clinical Trial

Finding: Single infusion of elamipretide showed dose-dependent improvements in left ventricular end-systolic volume, suggesting improved cardiac function.

Limitation: Single-dose study. Longer-term efficacy and safety not established. Heart failure population, not healthy aging.

See all 3 studies on the full SS-31 profile.

Frequently asked questions

How is SS-31 different from regular antioxidants?

Traditional antioxidants like vitamin C or E work by neutralizing free radicals after they are produced. SS-31 takes a fundamentally different approach — it stabilizes the mitochondrial membrane to prevent excessive ROS production in the first place. This upstream mechanism is why researchers consider it more promising than conventional antioxidant supplementation for mitochondrial dysfunction.

Why did SS-31 fail its Barth syndrome trial?

The pivotal phase III trial did not meet its primary endpoint (6-minute walk distance improvement) despite showing improvements in secondary endpoints like cardiac stroke volume and biomarkers. This is common in rare disease trials with small sample sizes and variable disease severity. The biological activity was real, but the trial design may not have captured it in the primary outcome.

Is SS-31 related to MOTS-c?

Both target mitochondria but through completely different mechanisms. MOTS-c is a naturally occurring mitochondrial-derived peptide that activates AMPK signaling. SS-31 is a synthetic peptide that directly stabilizes the inner mitochondrial membrane. They represent complementary approaches to mitochondrial health and are sometimes discussed together in longevity circles.

Full SS-31 Profile

Evidence, timeline, products & more

Take the Peptide Quiz

Get personalized recommendations

Last updated: 2026-04-26

Medical Disclaimer

The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.